05/02/2008 - Lilly's credibility over their continuous PR on how they are going to pay out $1.2 billion in Zyprexa damages Many claimants are being stonewalled. More>>>

04/20/2008 - “Based on these findings we concluded that male rats treated with olanzapine experienced an early disruption of energy metabolism. More >>>

04/07/2008 - Eli Lilly and Co.'s storied history was on full display last week as Sidney Taurel, a career Lilly man, retired as chief executive and was replaced by John Lechleiter, another career Lilly man. More>>>

04/06/2008 - Some fast facts on the Zyprexa controversy chronicled by a patient user. More>>>

04/04/2008 - Attorney General Richard Blumenthal sues Eli Lilly and Company, Inc. for illegally marketing its anti psychotic drug Zyprexa for unapproved uses, and concealing the drug's serious side effects, for more than a decade. More>>>

More News ::

Zyprexa ( Zyprexa Olanzapine ) is an anti-psychotic medication that was approved in 1996 by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia. It is often prescribed for other problems such as anxiety and depression. Zyprexa is a member of a class of drugs commonly referred to as "second generation anti-psychotics" ("SGA's") or "atypical anti-psychotics." When Zyprexa ( Olanzapine ) was approved in 1996, there were 2 other such SGA medications already available on the market. Consequently, Zyprexa is considered a "me-too" drug, joining a class of existing medications prescribed for the treatment of common disorders.

The SGA's were developed as an alternative to the so-called "first generation anti-psychotics" ("FGA's"). The SGA's were designed to be more effective in the treatment of anti-psychotic disorders with fewer of the side effects generally associated with the use of FGA's.

Of six SGA's currently available, Zyprexa is the most commonly prescribed. The generic name of Zyprexa is olanzapine. Zyprexa has been prescribed to more than 14 million people in 84 countries since its approval in 1996.


In September 2003, the FDA ordered Eli Lilly to revise Zyprexa's label by adding a side effects warning that "hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical anti-psychotics." Among the more serious outcomes resulting from hyperglycemic abnormalities are diabetes, diabetic ketoacidosis, diabetic coma and, in some cases death. * Zyprexa weight gain is also a commonly reported side effect.

- Diabetes
- Diabetic Ketoacidosis
- Diabetic Coma
- Hyperosmolar Coma
- Hyperglycemia

If you are currently taking Zyprexa and have concerns about its safetly, you should consult with your doctor regarding your treatment options. Under no circumstances should you discontinue taking any medication, including Zyprexa, without first consulting with your doctor. For Zyprexa legal information contact the Zyprexa Attorneys of Ennis & Ennis, P.A. by filling out our free Zyrpexa case evaluation form or by calling the toll-free number listed below.